Recipient non-hematopoietic tissues

Recipient non-hematopoietic tissues refer to the host's physiological structures that do not belong to the myeloid or lymphoid lineages, primarily including the skin, liver, and gastrointestinal tract. In the clinical context of allogeneic hematopoietic stem cell transplantation (HSCT), these tissues serve as the primary anatomical sites of injury in Graft-versus-Host Disease (GvHD) (Shlomchik, W. D., Nature Reviews Immunology, 2007). The pathology involves donor-derived T cells recognizing host antigens presented by these tissues, leading to inflammatory damage, epithelial apoptosis, and loss of barrier integrity (Zeiser, R., & Blazar, B. R., New England Journal of Medicine, 2017). While not a single molecular target, these tissues are the focus of therapeutic protection and monitoring; drugs such as ruxolitinib and corticosteroids are used to mitigate the immune-mediated destruction of these compartments (Toubai, T., & Magenau, J., Blood, 2020). Furthermore, research into tissue-specific protective agents like Palifermin aims to enhance the resilience and repair of these non-hematopoietic sites to improve transplant outcomes (Hanash, A. M., et al., Nature Medicine, 2012).

Other names

Host non-hematopoietic cellsRecipient parenchymal tissuesGvHD target organsNon-hematopoietic host compartment

Immunosuppression of donor T-cells, inhibition of cytokine signaling (JAK/STAT), and stimulation of epithelial repair and growth factors.